{
    "clinical_study": {
        "@rank": "94105", 
        "arm_group": {
            "arm_group_label": "Radium-223 dichloride", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of the best standard of care plus BAY88-8223 in Japanese\n      patients with CRPC and bone metastases after a multiple administration"
        }, 
        "brief_title": "Japanese BAY88-8223 Monotherapy Phase II Study", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostatic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have received docetaxel or not eligible for the first course of docetaxel, i.e.\n             patients who are not fit enough and willing.\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate\n\n          -  Multiple bone metastases\n\n          -  Either regular (not occasional) analgesic medication use for cancer-related bone pain\n             or treatment with external beam radiotherapy (EBRT) for bone pain.\n\n          -  Best standard of care(BSoC) is regarded as the routine standard of care.\n\n        Exclusion Criteria :\n\n          -  Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the\n             treatment period\n\n          -  History of visceral metastasis, or presence of visceral metastasis"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929655", 
            "org_study_id": "16430"
        }, 
        "intervention": {
            "arm_group_label": "Radium-223 dichloride", 
            "description": "BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration", 
            "intervention_name": "Radium-223 dichloride (Xofigo, BAY88-8223)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Succinylcholine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phase II", 
            "symptomatic castration-resistant prostate cancer", 
            "bone metastases"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-8577"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-8543"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "003-0804"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanazawa", 
                        "country": "Japan", 
                        "state": "Ishikawa", 
                        "zip": "920-8641"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "236-0004"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sendai", 
                        "country": "Japan", 
                        "state": "Miyagi", 
                        "zip": "980-8574"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osakasayama", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "589-8511"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "565-0871"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu", 
                        "country": "Japan", 
                        "state": "Shizuoka", 
                        "zip": "431-3192"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8603"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-8431"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "135-8550"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "160-8582"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "260-8717"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "812-8582"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto", 
                        "country": "Japan", 
                        "zip": "860-0008"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Okayama", 
                        "country": "Japan", 
                        "zip": "700-8558"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of change in total alkaline phosphatase from baseline at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929655"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of change in total alkaline phosphatase at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 weeks"
            }, 
            {
                "measure": "Percentages of change in bone ALP at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks"
            }, 
            {
                "measure": "Percentages of change in bone ALP at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have total alkaline phosphatase normalization at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have total alkaline phosphatase normalization at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have bone alkaline phosphatase normalization at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "The proportion of subjects who have bone alkaline phosphatase normalization at the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Time to prostate specific antigen progression", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}